Project Details
Description
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line Systemic Treamtent for Hepatocellular Carcinoma (HCC)
| Status | Finished |
|---|---|
| Effective start/end date | 10/13/09 → 10/31/15 |
Funding
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.